Call centre software producer Replicant closed a $78m series B round backed by Salesforce Ventures while Ashvattha Therapeutics raised $69m from investors including strategic partner Huadong Medicine.

Omri Green has departed from venture firm Grove Ventures and will take on an Israel-based partner role at Dell Technologies Capital.

Vishal Gupta, formerly a director at the SoftBank division that oversees its Vision Funds, has joined TA Associates in a similar role.

GAC has returned to lead the Tencent and Guangzhou Public Transport-backed automated taxi developer’s latest round, which included WeRide and Pony.ai.

GS Group contributed to a series B round that pushed messenger RNA therapeutics and vaccine developer RVAC Medicines' overall funding to $140m.

Corporate-backed medical imaging technology producer Lunit is preparing to float in South Korea while cancer drug developer Pheast secured $76m from investors including Alexandria Venture Investments.

Massachusetts Mutual Life's venture capital arm has formed a fourth fund, which will concentrate on European and Asia-Pacific investments.

Yangtze River Pharmaceutical Group led Binhui Biopharm's $47m series B-plus round while Sigfox has been snapped up by UnaBiz for under $30m after raising over $300m.

The Sinopharm-backed laboratory animal model developer floated on Shanghai Stock Exchange’s Star Market two years after its last equity funding.

Web3 security software producer Certik received $60m from investors including SoftBank Vision Fund 2 while corporate-backed automation technology provider Vicarious is being bought after raising over $250m.